Kesimpta is Novartis’s brand of ofatumumab, a once-monthly anti-CD20 injection for relapsing forms of multiple sclerosis. You give it to yourself at home with a prefilled pen, which sounds like it should make it the cheap option. It is not.
What the pen actually changes is which side of your benefits it lands on. Kesimpta is dispensed through a specialty pharmacy and priced under the pharmacy benefit. The infusions it competes with (Ocrevus, Briumvi and Tysabri) are given by a clinician and priced under the medical benefit, with a separate administration charge stacked on top. Those are two different pricing systems, and comparing them honestly is the point of this guide. Every figure below was researched September 4, 2026.
What Does Kesimpta Cost Without Insurance?
Three independent sources price the pen and they agree closely. Novartis’s own cost page states a wholesale acquisition cost of $10,094.84 per month for a 20 mg dose as of May 1, 2026, with a footnote defining a month as once every four weeks. CMS’s National Average Drug Acquisition Cost survey, which measures what pharmacies actually pay, lists the Kesimpta 20 mg / 0.4 mL pen at $24,380.23 per milliliter effective August 19, 2026, which is $9,752.09 for the 0.4 mL pen. CMS’s Medicare Part D spending file shows an average of $9,714.02 per prescription claim across 59,976 Kesimpta claims in 2024.
The infusion figures come from Medicare’s Part B payment limit file effective July 1 through September 30, 2026, and from CMS’s 2024 national claims data, which reports what providers billed next to what Medicare allowed.
| Cost item | Low | Typical | High |
|---|---|---|---|
| Kesimpta, one 20 mg pen | $9,714.02 | $9,752.09 | $10,094.84 |
| Kesimpta, one year at 13 doses | $126,282 | $126,777 | $131,233 |
| Ocrevus (ocrelizumab, J2350), one 600 mg infusion | $32,342.77 | $36,582.00 | $79,337.44 |
| Briumvi (ublituximab, J2329), one 450 mg infusion | $27,600.08 | $32,507.55 | $67,908.74 |
| Tysabri (natalizumab, J2323), one 300 mg infusion | $6,567.26 | $7,321.80 | $15,756.78 |
| IV infusion administration, first hour (CPT 96365) | $60.45 | $217.31 | $222.72 |
| IV infusion administration, each added hour (CPT 96366) | $19.46 | $47.84 | $89.59 |
For the three infusions, the low column is the average Medicare allowed amount in 2024, the typical column is the July 2026 Part B payment limit, and the high column is the average charge providers actually submitted in 2024. Those payment limits reset October 1, 2026, so re-check them after that date.
Dosing matters as much as unit price here. Per each product’s FDA prescribing information, Ocrevus maintenance is 600 mg every six months, Briumvi maintenance is 450 mg every 24 weeks, and Tysabri is 300 mg every four weeks. At the July 2026 payment limits that is about $73,164 a year for Ocrevus, $65,015 for Briumvi and $95,183 for Tysabri, before any administration fee. Kesimpta at Novartis’s list price is roughly $131,233. The self-injected pen is the most expensive of the four on paper.
One caveat on the Briumvi row: only 329 Medicare beneficiaries nationally had a J2329 claim in the 2024 file, a small denominator compared with 5,160 for Ocrevus and 1,501 for Tysabri, so treat the billed-charge average as indicative rather than settled.
What Drives the Price
Pharmacy benefit versus medical benefit
This is the biggest structural difference. A Kesimpta pen is a pharmacy claim, so what you owe is a copay or coinsurance on a drug, and there is exactly one line item. An MS infusion is a medical claim, so you get a drug line under its HCPCS code plus an administration line under CPT 96365 and 96366, and often a facility or clinic visit charge as well.
The administration fee is a separate, negotiable bill
Medicare’s 2024 claims data shows the size of the gap. For CPT 96365, the first hour of intravenous infusion, providers submitted an average charge of $222.72 in an office setting while Medicare allowed $60.45, a ratio of about 3.7 to 1. For each additional hour under 96366 the split was $89.59 submitted against $19.46 allowed. If the infusion is billed as a complex or chemotherapy-style administration under CPT 96413, the submitted average jumps to $481.33 against $125.21 allowed.
Site of care
The same infusion code pays very differently depending on where you sit. In a hospital outpatient department, the July 2026 OPPS rate for 96365 is $217.31, roughly three and a half times the $60.45 Medicare allowed in a physician office. A freestanding infusion suite or a neurologist’s office is usually the cheaper building for the identical service. This is the same dynamic covered in our guide to iron infusion costs.
Nothing cheaper to switch to
CMS’s acquisition-cost record for the Kesimpta pen carries no corresponding generic price at all, because there is no generic version to price. That is normal for a biologic, and it is why the three sources above land within 4% of each other instead of scattering the way a generic tablet’s prices do. Nothing here carries the competitive pressure that collapses a small-molecule price.
Loading doses in year one
Kesimpta’s label calls for 20 mg at weeks 0, 1 and 2, then monthly starting at week 4. That means the first year carries extra pens, so a first-year cash estimate should be higher than the steady-state figure in the table.
Cash Price vs. Insurance
For most drugs on this site, paying cash sometimes beats using insurance. For Kesimpta it does not, and it is worth saying plainly. At roughly $10,000 a dose there is no cash discount structure, no coupon and no pharmacy shopping strategy that changes the number materially. The three sources above span less than 4%, which tells you the price is essentially fixed.
The manufacturer copay card does not help a cash payer either. The Novartis Co-Pay Plus program terms state it is “valid only for those with private insurance,” with a combined annual limit of $18,000, and that the program is not valid where the patient is not using insurance coverage at all or under Medicare, Medicaid, TRICARE, VA or DoD. The Bridge Program, which supplies up to 15 free doses during a coverage appeal, also requires commercial insurance and a prior-authorization denial. Both are designed for insured patients.
What that leaves for someone with no coverage is the free-drug route. Novartis’s own cost page directs uninsured patients to the Novartis Patient Assistance Foundation, an independent 501(c)(3) that provides Novartis medicines at no cost to patients who are uninsured or have government insurance, meet income guidelines and live in the US or a US territory. Kesimpta is on its medication list. Novartis moved new and re-enrolling patients to a new enrollment portal effective July 27, 2026, so use the current forms rather than an old PDF.
How to Pay Less
Apply to the Novartis Patient Assistance Foundation first. This is the only route that takes the price to zero for an uninsured patient. Expect to submit proof of income, and note that NPAF will not supply the drug to someone whose plan runs an alternate funding program.
Check whether you qualify for Medicaid or a marketplace plan before you pay anything. At $126,000 a year, coverage is worth more than any discount. Medicare Part D now caps what a beneficiary pays out of pocket for covered drugs each year, and a marketplace plan caps it too, which turns a six-figure drug into a four-figure one.
Ask the neurologist whether an infusion in a low-cost setting is cheaper for your situation. At the July 2026 Medicare allowances, Ocrevus and Briumvi both cost less per year than Kesimpta’s list price. Whether that holds for you depends on the site of care and the administration fee, which is exactly the number to get in writing before you book.
Get the infusion quote itemized. If you do go the infusion route, ask for the drug HCPCS code, the administration CPT codes and the facility fee separately. Our guide to reading an itemized hospital bill walks through what to look for, and a billed-versus-allowed gap of three to five times on the administration line is normal, not a mistake.
Negotiate the administration line, not the drug line. The drug is close to fixed. The infusion fee is not. Medicare’s national allowed amounts above give you a defensible anchor when you ask for a self-pay rate. Our medical bill negotiation guide covers the script, and if the infusion happened at a nonprofit hospital, check hospital charity care before you agree to a payment plan.
Look at independent foundations if you have any insurance at all. As of September 4, 2026 the PAN Foundation’s multiple sclerosis fund is open and awards up to $8,000 a year, but it requires government-funded coverage such as Medicare, Medicaid or TRICARE. Foundation funds open and close without notice, so check status the day you apply rather than trusting a page you read last month.
The Bottom Line
Kesimpta is about $9,714 to $10,095 a dose and there is no cash strategy that meaningfully lowers that. The useful decisions are upstream of the price: whether you can get covered at all, whether the free-drug program applies to you, and if you end up on an infusion instead, which building it happens in. Compare a specific quote against Medicare’s published national rates with our fair price tool before you accept it, and see our Leqembi cost guide for how the same medical-benefit math plays out in another neurology infusion.